XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
XOMAXOMA(XOMA) GlobeNewswire News Room·2024-08-13 19:30

Cash receipts totaled 22.6millionin2Q24,inclusiveofroyaltyincomeandmilestonesfrom DayOnePharmaceuticalsandRezoluteExpandedthecommercialroyaltyandmilestoneportfoliowiththeacquisitionof economicinterestsinXACIATO™(clindamycinphosphate)vaginalgel222.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potential royalty streams, as well as more than 9.5 million in non-dilutive capital EMERYVILLE, Calif., Aug. 1 ...